The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 227.50
Bid: 226.50
Ask: 228.00
Change: 2.00 (0.89%)
Spread: 1.50 (0.662%)
Open: 228.00
High: 228.50
Low: 224.50
Prev. Close: 225.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

Fri, 17th Nov 2023 07:58

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

UK retail sales declined last month despite expectations of a month-on-month increase, and declined faster than expected on an annual basis, official numbers on Friday showed.

"Cost of living pressures, reduced footfall and the great British weather all played their part. There are signs that cracks are starting to appear in the economy with consumers tightening their belts and switching to cheaper brands. Consumers are still spending more and getting less with retail sales volumes now at their lowest level since February 2021," said Wealth Club's Charlie Huggins.

Meanwhile, Swissquote Bank analyst Ipek Ozkardeskaya was upbeat ahead of the final day of trading this week, particularly when reflecting upon the week's news coming out of the US.

"This week could hardly be better in terms of economic, political, and geopolitical news. The US inflation slowed more than expected, the US politicians inked a short-term deal to avert a shutdown," said Ozkardeskaya.

"On top, the US retail sales fell last month, but fell less than expected, the initial jobless claims rose, and the US unemployment benefits reached the highest level in almost two years, factory production fell more than expected and homebuilder sentiment fell to the lowest level for the year."

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called up 0.4% at 7,441.17

----------

Hang Seng: down 2.1% at 17,452.71

Nikkei 225: closed up 0.5% at 33,585.20

S&P/ASX 200: closed down 0.1% at 7,049.40

----------

DJIA: closed down 45.74 points, or 0.1%, at 34,945.47

S&P 500: closed up 5.36 points, or 0.1%, at 4,508.24

Nasdaq Composite: closed up 9.84 points, or 0.1%, at 14,113.67

----------

EUR: down at USD1.0839 (USD1.0840)

GBP: down at USD1.2377 (USD1.2398)

USD: down at JPY150.50 (JPY151.34)

Gold: up at USD1,986.42 per ounce (USD1,966.26)

(Brent): down at USD77.41 a barrel (USD80.84)

(changes since previous London equities close)

----------

ECONOMICS

----------

Friday's key economic events still to come:

10:00 CET EU balance of payments

11:00 CET EU CPI

08:30 EST US housing starts

08:30 CST US Fed Chicago President Austan Goolsbee speaks

10:00 EST US advance quarterly services

US FRB Boston President Susan Collins speaks

US Federal Reserve Board Vice Chair Michael Barr speaks

UK BoE Deputy Governor David Ramsden speaks

----------

According to the Office for National Statistics, retail sales volumes declined 2.7% year-on-year in October, quickening from a 1.3% decline in September. The September figure was revised from a previous 1.0% decline. The October read also came in worse than feared, with market expectations of a 1.5% decline, according to FXStreet-cited consensus. Retail sales declined 0.3% in October from September, falling short of consensus. A monthly increase of 0.3% was forecast, according to FXStreet. In September, retail sales had fallen 1.1% from August, revised from a previous 0.9% decline. "Non-food stores sales volumes fell by 0.2% in October 2023, following a 2.1% fall in September 2023; retailers suggested that cost of living, reduced footfall and the wet weather in the second half of the month contributed to the fall," the ONS noted.

----------

US President Joe Biden has signed a temporary spending bill a day before a potential government shutdown. The move pushes a fight with congressional Republicans over the federal budget into the new year, and wartime aid for Ukraine and Israel remains stalled. The measure passed the US house and senate by wide bipartisan margins this week, ensuring the government remains open until after the holiday season. It also potentially giving legislators more time to sort out their considerable differences over government spending levels for the current fiscal year. Biden signed the bill in San Francisco, where he is hosting the summit of Asia-Pacific Economic Co-operation economies.

----------

BROKER RATING CHANGES

----------

Barclays raises NatWest to 'overweight' (equal weight) - price target 330 (315) pence

----------

Barclays raises Babcock International to 'overweight' (equal weight) - price target 529 (325) pence

----------

Jefferies cuts Great Portland Estates to 'underperform' (hold) - price target 352 (387) pence

----------

COMPANIES - FTSE 100

----------

AstraZeneca said its Truqap treatment for patients with advanced hormone receptor positive breast cancer, in combination with Faslodex, has been approved by the US Food & Drug Administration. This follows the results from its CapItello-291 phase 3 trial published earlier this year, which showed reduced risk of disease progression or death by 50% compared to Faslodex alone. AstraZeneca Executive Vice President, Oncology Business Unit Dave Fredrickson commented: "The rapid US approval of Truqap reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need to test patients at the time of diagnosis, as up to fifty per cent have tumours with these alterations. As a first-in-class medicine, this approval provides a critical new option for patients in the US with this specific type of disease and we look forward to bringing Truqap to the many breast cancer patients who can benefit across the globe."

----------

COMPANIES - FTSE 250

----------

PureTech Health said its founded entity Karuna Therapeutics has announced positive results from its phase 1b ambulatory blood pressure monitoring trial of KarXT in treating schizophrenia. The biotechnology firm said results demonstrate that KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia. This is alongside meeting its primary endpoint of demonstrating a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of negative 0.59 millimetres of mercury. It said KarXT was "generally well tolerated", with a side effect profile consistent with prior trials in the Emergent programme evaluating KarXT in schizophrenia.

----------

OTHER COMPANIES

----------

FRP Advisory said its performance was strong during the half-year that ended October 31. The corporate finance, restructuring and debt adviser said it expects first half revenue of GBP58.7 million, up 19% from GBP49.4 million a year earlier, alongside underlying adjusted earnings before interest, tax, depreciation and amortisation rising 34% to GBP15.5 million from GBP11.6 million. It noted the restructuring having seen an increase in activity levels during calendar 2023, including administrations approaching pre-pandemic levels. The company said: "Companies with significant borrowings who have rolled off lower interest rate arrangements are now subject to much higher debt service costs, with interest rates now considerably higher than the 2009-2021 period...Certain sectors such as construction, property, casual dining and food service, retail, administrative and support services are finding current trading conditions particularly challenging." Chief Executive Officer Geoff Rowley added: "We remain confident of making further progress, with leading positions in our core markets and a team and structure that leaves us well positioned to support corporates through the business cycle and respond to increased demand for our services."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
5 Jan 2021 17:55

UK EXECUTIVE CHANGE SUMMARY: Saga Insurance CEO Resigns After One Year

UK EXECUTIVE CHANGE SUMMARY: Saga Insurance CEO Resigns After One Year

Read more
5 Jan 2021 08:26

PureTech appoints George Farmer as new finance chief

(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health announced on Tuesday that George Farmer has been appointed chief financial officer.

Read more
11 Dec 2020 21:47

IN BRIEF: PureTech Starts Phase 2a Trial Of LYT-100 In Lymphedema

IN BRIEF: PureTech Starts Phase 2a Trial Of LYT-100 In Lymphedema

Read more
11 Dec 2020 20:33

IN BRIEF: PureTech Starts Trial Of LYT-200 In Metastatic Solid Tumors

IN BRIEF: PureTech Starts Trial Of LYT-200 In Metastatic Solid Tumors

Read more
3 Dec 2020 17:55

IN BRIEF: PureTech Health Starts Phase Two Trial Of LYT-100

IN BRIEF: PureTech Health Starts Phase Two Trial Of LYT-100

Read more
27 Nov 2020 15:35

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert To Leave Asia Focus Fund

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert To Leave Asia Focus Fund

Read more
27 Nov 2020 15:05

UK DIRECTOR DEALINGS SUMMARY: New Amigo Leadership Team Buys Shares

UK DIRECTOR DEALINGS SUMMARY: New Amigo Leadership Team Buys Shares

Read more
23 Nov 2020 15:42

UK DIRECTOR DEALINGS SUMMARY: Outgoing Grainger CFO Sells 25,000

UK DIRECTOR DEALINGS SUMMARY: Outgoing Grainger CFO Sells 25,000

Read more
19 Nov 2020 15:56

UK DIRECTOR DEALINGS SUMMARY: Menzies Non-Exec Turns GBP58,000 Profit

UK DIRECTOR DEALINGS SUMMARY: Menzies Non-Exec Turns GBP58,000 Profit

Read more
18 Nov 2020 20:23

IN BRIEF: PureTech Says LYT-100 Well Tolerated In Food Effect Study

IN BRIEF: PureTech Says LYT-100 Well Tolerated In Food Effect Study

Read more
13 Nov 2020 16:20

IN BRIEF: PureTech To Begin Nasdaq Trading On Monday

IN BRIEF: PureTech To Begin Nasdaq Trading On Monday

Read more
12 Nov 2020 19:17

UK TRADING UPDATE SUMMARY: Clipper Expects 20% Interim Revenue Climb

UK TRADING UPDATE SUMMARY: Clipper Expects 20% Interim Revenue Climb

Read more
11 Nov 2020 20:17

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus

Read more
28 Oct 2020 17:43

UK TRADING UPDATE SUMMARY: Shoe Zone Ends Financial Year On Back Foot

UK TRADING UPDATE SUMMARY: Shoe Zone Ends Financial Year On Back Foot

Read more
28 Oct 2020 08:01

PureTech Health eyes Nasdaq listing for ADS

(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health has filed a public registration statement to the US Securities and Exchange Commission as it looks to list its American depository shares on the Nasdaq.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.